Changing epidemiology of cirrhosis from 2010 to 2019: results from the Global Burden Disease study 2019

References

• Ginès P, Krag A, Abraldes JG, et al. Liver cirrhosis. Lancet. 2021;398(10308):1–12. doi:10.1016/S0140-6736(21)01374-X.
   PubMed Web of Science ®Google Scholar
• Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37–55. doi:10.1016/j.mam.2018.09.002.
   PubMed Web of Science ®Google Scholar
• D’Amico G, Morabito A, D’Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol. 2018;68(3):563–576. doi:10.1016/j.jhep.2017.10.020.
   PubMed Web of Science ®Google Scholar
• Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12(1):145. doi:10.1186/s12916-014-0145-y.
   PubMedGoogle Scholar
• Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171. doi:10.1016/j.jhep.2018.09.014.
   PubMed Web of Science ®Google Scholar
• GBD 2019 Hepatitis B Collaborators. Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Gastroenterol Hepatol. 2022;7(9):796–829.
   PubMed Web of Science ®Google Scholar
• NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016;387(10027):1513–1530.
   PubMed Web of Science ®Google Scholar
• NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–2642. doi:10.1016/S0140-6736(17)32129-3.
   PubMed Web of Science ®Google Scholar
• GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245–266.
   PubMed Web of Science ®Google Scholar
• Paik JM, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology. 2020;72(5):1605–1616. doi:10.1002/hep.31173.
   PubMed Web of Science ®Google Scholar
• Ye F, Zhai M, Long J, et al. The burden of liver cirrhosis in mortality: results from the global burden of disease study. Front Public Health. 2022;10:909455. doi:10.3389/fpubh.2022.909455.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang X, Liu M, et al. Global, regional, and national burden of cirrhosis and other chronic liver diseases due to alcohol use, 1990–2019: a systematic analysis for the global burden of disease study 2019. BMC Gastroenterol. 2022;22(1):484. doi:10.1186/s12876-022-02518-0.
   PubMed Web of Science ®Google Scholar
• Liu Y, Sun Z, Wang Q, et al. Contribution of alcohol use to the global burden of cirrhosis and liver cancer from 1990 to 2019 and projections to 2044. Hepatol Int. 2023;17(4):1028–1044.
   PubMed Web of Science ®Google Scholar
• GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222. doi:10.1016/S0140-6736(20)30925-9.
   PubMed Web of Science ®Google Scholar
• Wang H, Abbas KM, Abbasifard M, et al. Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1160–1203. doi:10.1016/S0140-6736(20)30977-6.
   PubMed Web of Science ®Google Scholar
• Roerecke M, Shield KD, Higuchi S, et al. Estimates of alcohol-related oesophageal cancer burden in Japan: systematic review and meta-analyses. Bull World Health Organ. 2015;93(5):329–338c. doi:10.2471/BLT.14.142141.
   PubMed Web of Science ®Google Scholar
• Jiang H, Room R, Waleewong O, et al. Restricting alcohol consumption to reduce liver disease in the Asia-Pacific region. Lancet Gastroenterol Hepatol. 2020;5(2):105–107. doi:10.1016/S2468-1253(19)30322-X.
   PubMed Web of Science ®Google Scholar
• Pimpin L, Cortez-Pinto H, Negro F, et al. Burden of liver disease in Europe: epidemiology and analysis of risk factors to identify prevention policies. J Hepatol. 2018;69(3):718–735. doi:10.1016/j.jhep.2018.05.011.
   PubMed Web of Science ®Google Scholar
• Gorgani F, Esfahani Z, Ghamari SH, et al. Global, regional, and national burden and quality of care index of liver cirrhosis by cause from global burden of disease 1990-2019. J Gastroenterol Hepatol. 2023;38(1):119–128. doi:10.1111/jgh.16041.
   PubMed Web of Science ®Google Scholar
• Alcohol DaAB. Global status report on alcohol and health 2018. 2018.https://www.who.int/publications/i/item/9789241565639
   Google Scholar
• GBD 2020 Alcohol Collaborators. Population-level risks of alcohol consumption by amount, geography, age, sex, and year: a systematic analysis for the global burden of disease study 2020. Lancet. 2022;400(347):185–235.
   PubMedGoogle Scholar
• Alberts CJ, Clifford GM, Georges D, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022;7(8):724–735. doi:10.1016/S2468-1253(22)00050-4.
   PubMed Web of Science ®Google Scholar
• Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–861. doi:10.1016/S2468-1253(22)00165-0.
   PubMed Web of Science ®Google Scholar
• Huang DQ, Singal AG, Kono Y, et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022;34(7):969–977 e2. doi:10.1016/j.cmet.2022.05.003.
   PubMed Web of Science ®Google Scholar
• Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. J Hepatol. 2014;60(3):612–617. doi:10.1016/j.jhep.2013.10.020.
   PubMed Web of Science ®Google Scholar
• Grønbæk L, Otete H, Ban L, et al. Incidence, prevalence and mortality of autoimmune hepatitis in England 1997–2015. A population-based cohort study. Liver Int. 2020;40(7):1634–1644. doi:10.1111/liv.14480.
   PubMed Web of Science ®Google Scholar
• Bittermann T, Lewis JD, Levy C, et al. Sociodemographic and georaphic differences in the US epidemiology of autoimmune hepatitis with and without cirrhosis. Hepatology. 2023;77(2):367–378. doi:10.1002/hep.32653.
   PubMed Web of Science ®Google Scholar
• Gazda J, Drazilova S, Janicko M, et al. The epidemiology of primary biliary cholangitis in European countries: a systematic review and meta-analysis. Can J Gastroenterol Hepatol. 2021;2021:9151525–9151511. doi:10.1155/2021/9151525.
   PubMed Web of Science ®Google Scholar
• Trivedi PJ, Bowlus CL, Yimam KK, et al. Epidemiology, natural history, and outcomes of primary sclerosing cholangitis: a systematic review of population-based studies. Clin Gastroenterol Hepatol. 2022;20(8):1687–1700.e4. doi:10.1016/j.cgh.2021.08.039.
   PubMed Web of Science ®Google Scholar